Moderna (MRNA) Non-Current Assets (2017 - 2026)
Moderna (MRNA) posted quarterly Non-Current Assets of $5.1 billion for Q2 2026, down 11.87% year-over-year from $5.8 billion in Q2 2025, and down 10.0% on a QoQ basis from $5.7 billion in Q1 2026.
Moderna (MRNA) Non-Current Assets (2017 - 2026) Analysis & Trends
Moderna has reported Non-Current Assets for 10 years, with the latest figure at $5.1 billion in Q2 2026.
- Non-Current Assets for Q2 2026 came in at $5.1 billion, down 11.87% year-over-year; the trailing twelve-month figure through Jun 2026 was $22.2 billion (down 7.35% YoY), and the FY2025 annual result was $5.8 billion, down 4.12% from the prior year.
- Non-Current Assets eased to $5.1 billion in Q2 2026, from $5.7 billion in the prior quarter.
- Over five years, Non-Current Assets peaked at $12.5 billion in Q2 2022 and troughed at $5.1 billion in Q2 2026.
- A 5-year average of $8.2 billion and a median of $6.6 billion in 2024 frame the typical range for Non-Current Assets.
- The widest annual swing landed in 2022, when Non-Current Assets jumped 1036.13%; it then sank 46.66% in 2024.
- A 5-year view of Non-Current Assets shows it stood at $12.4 billion in 2022, then tumbled by 34.81% to $8.1 billion in 2023, then declined by 25.4% to $6.0 billion in 2024, then retreated by 4.12% to $5.8 billion in 2025, then decreased by 11.18% to $5.1 billion in 2026.
- Per Business Quant data, the three most recent Non-Current Assets figures were $5.1 billion in Q2 2026, $5.7 billion in Q1 2026, and $5.8 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Moderna | 25.26 Bn | 20.13 Bn | 52.00 Mn | 5.15 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.15 Bn |
| Mar 31, 2026 | 5.72 Bn |
| Dec 31, 2025 | 5.79 Bn |
| Sep 30, 2025 | 5.54 Bn |
| Jun 30, 2025 | 5.84 Bn |
| Mar 31, 2025 | 5.94 Bn |
| Dec 31, 2024 | 6.04 Bn |
| Sep 30, 2024 | 6.14 Bn |
| Jun 30, 2024 | 6.02 Bn |
| Mar 31, 2024 | 7.13 Bn |
| Dec 31, 2023 | 8.10 Bn |
| Sep 30, 2023 | 8.65 Bn |
| Jun 30, 2023 | 11.29 Bn |
| Mar 31, 2023 | 12.00 Bn |
| Dec 31, 2022 | 12.43 Bn |
| Sep 30, 2022 | 11.76 Bn |
| Jun 30, 2022 | 12.48 Bn |
| Mar 31, 2022 | 11.26 Bn |
| Dec 31, 2021 | 8.60 Bn |
| Sep 30, 2021 | 7.50 Bn |